Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction-Reference-Cited by-同舟云学术

Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction

Published:2001-08 Issue:9282 Volume:358 Page:605-613
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Publisher

Elsevier BV

Subject

General Medicine

Reference14 articles.

1. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial;Lancet,1999

2. Thrombolysis for acute myocardial infarction;White;Circulation,1998

3. Fibrinolysis for acute myocardial infarction. Current status and new horizons for pharmacological reperfusion, part I;Armstrong;Circulation,2001

4. Low molecular weight heparins in the treatment of acute coronary syndromes;Turpie;Arch Intern Med,2001

5. A randomized comparison of low-molecular-weight heparin enoxaparin and unfractionated heparin adjunctive to t-PA thrombolysis and aspirin (HART II);Ross;Circulation,2001

Cited by 526 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Future of Fibrinolysis Agents;Biochemistry;2024-07-22

2. A bibliometric analysis of tenecteplase research utilizing a commonly used citation index;Clinical Neurology and Neurosurgery;2024-02

3. Update on the Pharmacological Actions of Enoxaparin in Nonsurgical Patients;Medicina;2024-01-15

4. Biosimilarity. Do not confuse biosimilar and biocopy. Example of tenecteplase;Annales Pharmaceutiques Françaises;2023-11

5. 2023 ESC Guidelines for the management of acute coronary syndromes;European Heart Journal: Acute Cardiovascular Care;2023-09-22